Myocardial Infarction - Pipeline Review, H1 2016

Published: Apr, 2016 | Pages: 358 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Myocardial Infarction - Pipeline Review, H1 2016

Summary

Global Markets Direct's, ‘Myocardial Infarction - Pipeline Review, H1 2016', provides an overview of the Myocardial Infarction pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Myocardial Infarction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myocardial Infarction and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Myocardial Infarction
- The report reviews pipeline therapeutics for Myocardial Infarction by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Myocardial Infarction therapeutics and enlists all their major and minor projects
- The report assesses Myocardial Infarction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Myocardial Infarction

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Myocardial Infarction
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Myocardial Infarction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Content
Table of Contents 2

List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Myocardial Infarction Overview 11
Therapeutics Development 12
Pipeline Products for Myocardial Infarction - Overview 12
Pipeline Products for Myocardial Infarction - Comparative Analysis 13
Myocardial Infarction - Therapeutics under Development by Companies 14
Myocardial Infarction - Therapeutics under Investigation by Universities/Institutes 19
Myocardial Infarction - Pipeline Products Glance 21
Late Stage Products 21
Clinical Stage Products 22
Early Stage Products 23
Unknown Stage Products 24
Myocardial Infarction - Products under Development by Companies 25
Myocardial Infarction - Products under Investigation by Universities/Institutes 30
Myocardial Infarction - Companies Involved in Therapeutics Development 32
Amarantus Bioscience Holdings, Inc. 32
Angion Biomedica Corp. 33
Asterias Biotherapeutics, Inc. 34
AstraZeneca Plc 35
Athersys, Inc. 36
Bayer AG 37
Bharat Biotech International Limited 38
BioCardia, Inc. 39
Biscayne Pharmaceuticals, Inc. 40
Capricor Therapeutics, Inc. 41
CellProthera 42
Celyad SA 43
Compugen Ltd. 44
CSL Limited 45
Cynata Therapeutics Limited 46
FibroGen, Inc. 47
Hemostemix Ltd 48
Human Stem Cells Institute 49
HUYA Bioscience International, LLC 50
Immune Pharmaceuticals Inc. 51
Juventas Therapeutics, Inc. 52
Laboratoires Pierre Fabre SA 53
Lee's Pharmaceutical Holdings Limited 54
LegoChem Biosciences, Inc 55
LG Life Science LTD. 56
Medestea Research & Production S.p.A. 57
Mesoblast Limited 58
miRagen Therapeutics, Inc. 59
Moderna Therapeutics, Inc. 60
MorphoSys AG 61
NeuroVive Pharmaceutical AB 62
New World Laboratories, Inc. 63
Novartis AG 64
Omeros Corporation 65
Otsuka Holdings Co., Ltd. 66
Pfizer Inc. 67
Polyphor Ltd. 68
Primary Peptides, Inc. 69
Quantum Genomics SA 70
Quark Pharmaceuticals, Inc. 71
Recardio GmbH 72
Serodus ASA 73
Silver Creek Pharmaceuticals, Inc. 74
Stealth BioTherapeutics Inc. 75
Stemedica Cell Technologies, Inc. 76
Stempeutics Research Private Limited 77
TaiGen Biotechnology Co., Ltd. 78
Targazyme, Inc. 79
The International Biotechnology Center (IBC) Generium 80
TiGenix NV 81
Vicore Pharma AB 82
XBiotech USA, Inc. 83
Yuyu Pharma, Inc. 84
Zydus Cadila Healthcare Limited 85
Myocardial Infarction - Therapeutics Assessment 86
Assessment by Monotherapy Products 86
Assessment by Combination Products 87
Assessment by Target 88
Assessment by Mechanism of Action 92
Assessment by Route of Administration 95
Assessment by Molecule Type 97
Drug Profiles 99
(sacubitril + valsartan) - Drug Profile 99
AB-002 - Drug Profile 102
ACP-01 - Drug Profile 104
Alda-1 - Drug Profile 106
alteplase biosimilar - Drug Profile 107
AMRS-001 - Drug Profile 108
ANG-4011 - Drug Profile 111
Antisense RNAi Oligonucleotide to Inhibit miR-92 for Myocardial Infarction - Drug Profile 112
AP-102 - Drug Profile 113
APO-1 - Drug Profile 114
balixafortide - Drug Profile 115
Biosimilar 3 for Rheumatoid Arthritis, Acute Myocardial Infarction and Inflammation - Drug Profile 116
BIS-5409 - Drug Profile 117
bococizumab - Drug Profile 118
burixafor - Drug Profile 119
C-21 - Drug Profile 121
C3BSGQR-3 - Drug Profile 123
C3BSGQR-4 - Drug Profile 124
CAP-1001 - Drug Profile 125
CAP-1002 - Drug Profile 126
cenderitide - Drug Profile 128
CGEN-856S - Drug Profile 130
CIGB-500 - Drug Profile 132
CM-1 - Drug Profile 133
Cryocell - Drug Profile 135
CSL-112 - Drug Profile 136
CTX-101 - Drug Profile 138
cyclosporine - Drug Profile 140
Drugs to Inhibit Alpha Myosin for Cardiovascular Disorders - Drug Profile 141
Drugs to Inhibit SIRT2 for Ischemic Stroke and Myocardial Infarction - Drug Profile 142
dutogliptin tartrate - Drug Profile 143
elamipretide - Drug Profile 145
Ephrin A-1 for Myocardial Infarction - Drug Profile 147
F-573 - Drug Profile 148
FG-6874 - Drug Profile 149
Gemacell - Drug Profile 150
Gene Therapy for Acute Myocardial Infarction - Drug Profile 151
HBI-3802 - Drug Profile 152
HYPER-IL-6 - Drug Profile 153
ICG-001 - Drug Profile 154
IS-20 - Drug Profile 155
JI-38 - Drug Profile 156
JVS-100 - Drug Profile 157
JVS-200 - Drug Profile 159
KR-33028 - Drug Profile 160
LC-280126 - Drug Profile 161
LWnt-3a - Drug Profile 163
Lysimab - Drug Profile 164
MGN-1374 - Drug Profile 165
MGN-6114 - Drug Profile 166
MIF-2 - Drug Profile 167
MIF-20 - Drug Profile 168
Monoclonal Antibodies to Inhibit IL-1a for Myocardial Infarction and Atherosclerosis - Drug Profile 169
Monoclonal Antibody Conjugates to Target Mannose Receptor for Myocardial Infarction - Drug Profile 170
MPC-150IM - Drug Profile 171
MPC-25IC - Drug Profile 173
Neu-2000 - Drug Profile 174
NP-202 - Drug Profile 176
NVP-019 - Drug Profile 178
NVX-308 - Drug Profile 179
NWL-53 - Drug Profile 180
Oligonucleotide for Oncology and Cardiovascular - Drug Profile 181
Oligonucleotides for Cardiometabolic Diseases and Renal diseases - Drug Profile 182
OMS-721 - Drug Profile 184
OPC-28326 - Drug Profile 186
Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Drug Profile 188
Peptide to Agonize Apelin Receptor for Diabetes and Heart Failure - Drug Profile 190
PF-05285401 - Drug Profile 191
Polyglactin 370 for Acute Myocardial Infarction - Drug Profile 196
PP-001 - Drug Profile 197
Protein to Agonize LRP5 and LRP6 for Myocardial Infarction and Critical Limb Ischemia - Drug Profile 198
ProtheraCytes - Drug Profile 199
QGC-101 - Drug Profile 201
QPCP-1 - Drug Profile 202
RBB-001 - Drug Profile 203
Recombinant Protein for Cardiovascular Diseases - Drug Profile 204
Recombinant Protein for Myocardial Infarction - Drug Profile 205
Recombinant Proteins to Agonize IGF-1R for Myocardial Infarction - Drug Profile 206
Recombinant Prourokinase - Drug Profile 207
remestemcel-L - Drug Profile 208
rivaroxaban - Drug Profile 212
RNAi Oligonucleotide for Myocardial Infarction - Drug Profile 218
salicylamine - Drug Profile 219
SER-130 - Drug Profile 220
Small Molecule for Myocardial Infarction - Drug Profile 221
Small Molecule for Reperfusion Injury and Heart Attack - Drug Profile 222
Small Molecule to Inhibit Blood Factor XIa for CAHD and Stroke - Drug Profile 223
Small Molecules for Myocardial Infarction and Inflammation - Drug Profile 224
Small Molecules to Antagonize Adenosine A2B Receptor for Asthma and Myocardial Infarction - Drug Profile 225
Small Molecules to Inhibit BAX for Myocardial Infarction - Drug Profile 226
Small Molecules to Inhibit MMP for Myocardial Infarction - Drug Profile 227
Small Molecules to Inhibit PARP for Immunology, Oncology, Cardiovascular and Metabolic Disorders - Drug Profile 228
Small Molecules to Inhibit PDE5 for Cardiovascular Disease - Drug Profile 229
Small Molecules to Scavenge Free Radicals for Oxidative Stress Related Disorders - Drug Profile 230
Stem Cell Therapy for Acute Myocardial Infarction - Drug Profile 231
Stem Cell Therapy for Cardiovacular Diseases - Drug Profile 232
Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease, Infectious Disease and Toxicology - Drug Profile 233
Stem Cell Therapy for Cardiovascular Diseases - Drug Profile 236
Stem Cell Therapy for Myocardial Infarction and Heart Failure - Drug Profile 238
Stempeucel - Drug Profile 239
Synthetic Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases - Drug Profile 242
TF-0023 - Drug Profile 243
THR-100 - Drug Profile 244
ticagrelor - Drug Profile 246
TZ-101 - Drug Profile 250
VN-100 - Drug Profile 252
ZK-001 - Drug Profile 253
Myocardial Infarction - Recent Pipeline Updates 255
Myocardial Infarction - Dormant Projects 330
Myocardial Infarction - Discontinued Products 339
Myocardial Infarction - Product Development Milestones 340
Featured News & Press Releases 340
Appendix 349
Methodology 349
Coverage 349
Secondary Research 349
Primary Research 349
Expert Panel Validation 349
Contact Us 349
Disclaimer 350

List of Tables

Number of Products under Development for Myocardial Infarction, H1 2016 20
Number of Products under Development for Myocardial Infarction - Comparative Analysis, H1 2016 21
Number of Products under Development by Companies, H1 2016 22
Number of Products under Development by Companies, H1 2016 (Contd..1) 23
Number of Products under Development by Companies, H1 2016 (Contd..2) 24
Number of Products under Development by Companies, H1 2016 (Contd..3) 25
Number of Products under Development by Companies, H1 2016 (Contd..4) 26
Number of Products under Investigation by Universities/Institutes, H1 2016 28
Comparative Analysis by Late Stage Development, H1 2016 29
Comparative Analysis by Clinical Stage Development, H1 2016 30
Comparative Analysis by Early Stage Development, H1 2016 31
Comparative Analysis by Unknown Stage Development, H1 2016 32
Products under Development by Companies, H1 2016 33
Products under Development by Companies, H1 2016 (Contd..1) 34
Products under Development by Companies, H1 2016 (Contd..2) 35
Products under Development by Companies, H1 2016 (Contd..3) 36
Products under Development by Companies, H1 2016 (Contd..4) 37
Products under Investigation by Universities/Institutes, H1 2016 38
Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 39
Myocardial Infarction - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2016 40
Myocardial Infarction - Pipeline by Angion Biomedica Corp., H1 2016 41
Myocardial Infarction - Pipeline by Asterias Biotherapeutics, Inc., H1 2016 42
Myocardial Infarction - Pipeline by AstraZeneca Plc, H1 2016 43
Myocardial Infarction - Pipeline by Athersys, Inc., H1 2016 44
Myocardial Infarction - Pipeline by Bayer AG, H1 2016 45
Myocardial Infarction - Pipeline by Bharat Biotech International Limited, H1 2016 46
Myocardial Infarction - Pipeline by BioCardia, Inc., H1 2016 47
Myocardial Infarction - Pipeline by Biscayne Pharmaceuticals, Inc., H1 2016 48
Myocardial Infarction - Pipeline by Capricor Therapeutics, Inc., H1 2016 49
Myocardial Infarction - Pipeline by CellProthera, H1 2016 50
Myocardial Infarction - Pipeline by Celyad SA, H1 2016 51
Myocardial Infarction - Pipeline by Compugen Ltd., H1 2016 52
Myocardial Infarction - Pipeline by CSL Limited, H1 2016 53
Myocardial Infarction - Pipeline by Cynata Therapeutics Limited, H1 2016 54
Myocardial Infarction - Pipeline by FibroGen, Inc., H1 2016 55
Myocardial Infarction - Pipeline by Hemostemix Ltd, H1 2016 56
Myocardial Infarction - Pipeline by Human Stem Cells Institute, H1 2016 57
Myocardial Infarction - Pipeline by HUYA Bioscience International, LLC, H1 2016 58
Myocardial Infarction - Pipeline by Immune Pharmaceuticals Inc., H1 2016 59
Myocardial Infarction - Pipeline by Juventas Therapeutics, Inc., H1 2016 60
Myocardial Infarction - Pipeline by Laboratoires Pierre Fabre SA, H1 2016 61
Myocardial Infarction - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2016 62
Myocardial Infarction - Pipeline by LegoChem Biosciences, Inc, H1 2016 63
Myocardial Infarction - Pipeline by LG Life Science LTD., H1 2016 64
Myocardial Infarction - Pipeline by Medestea Research & Production S.p.A., H1 2016 65
Myocardial Infarction - Pipeline by Mesoblast Limited, H1 2016 66
Myocardial Infarction - Pipeline by miRagen Therapeutics, Inc., H1 2016 67
Myocardial Infarction - Pipeline by Moderna Therapeutics, Inc., H1 2016 68
Myocardial Infarction - Pipeline by MorphoSys AG, H1 2016 69
Myocardial Infarction - Pipeline by NeuroVive Pharmaceutical AB, H1 2016 70
Myocardial Infarction - Pipeline by New World Laboratories, Inc., H1 2016 71
Myocardial Infarction - Pipeline by Novartis AG, H1 2016 72
Myocardial Infarction - Pipeline by Omeros Corporation, H1 2016 73
Myocardial Infarction - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 74
Myocardial Infarction - Pipeline by Pfizer Inc., H1 2016 75
Myocardial Infarction - Pipeline by Polyphor Ltd., H1 2016 76
Myocardial Infarction - Pipeline by Primary Peptides, Inc., H1 2016 77
Myocardial Infarction - Pipeline by Quantum Genomics SA, H1 2016 78
Myocardial Infarction - Pipeline by Quark Pharmaceuticals, Inc., H1 2016 79
Myocardial Infarction - Pipeline by Recardio GmbH, H1 2016 80
Myocardial Infarction - Pipeline by Serodus ASA, H1 2016 81
Myocardial Infarction - Pipeline by Silver Creek Pharmaceuticals, Inc., H1 2016 82
Myocardial Infarction - Pipeline by Stealth BioTherapeutics Inc., H1 2016 83
Myocardial Infarction - Pipeline by Stemedica Cell Technologies, Inc., H1 2016 84
Myocardial Infarction - Pipeline by Stempeutics Research Private Limited, H1 2016 85
Myocardial Infarction - Pipeline by TaiGen Biotechnology Co., Ltd., H1 2016 86
Myocardial Infarction - Pipeline by Targazyme, Inc., H1 2016 87
Myocardial Infarction - Pipeline by The International Biotechnology Center (IBC) Generium, H1 2016 88
Myocardial Infarction - Pipeline by TiGenix NV, H1 2016 89
Myocardial Infarction - Pipeline by Vicore Pharma AB, H1 2016 90
Myocardial Infarction - Pipeline by XBiotech USA, Inc., H1 2016 91
Myocardial Infarction - Pipeline by Yuyu Pharma, Inc., H1 2016 92
Myocardial Infarction - Pipeline by Zydus Cadila Healthcare Limited, H1 2016 93
Assessment by Monotherapy Products, H1 2016 94
Assessment by Combination Products, H1 2016 95
Number of Products by Stage and Target, H1 2016 97
Number of Products by Stage and Mechanism of Action, H1 2016 101
Number of Products by Stage and Route of Administration, H1 2016 104
Number of Products by Stage and Molecule Type, H1 2016 106
Myocardial Infarction Therapeutics - Recent Pipeline Updates, H1 2016 263
Myocardial Infarction - Dormant Projects, H1 2016 338
Myocardial Infarction - Dormant Projects (Contd..1), H1 2016 339
Myocardial Infarction - Dormant Projects (Contd..2), H1 2016 340
Myocardial Infarction - Dormant Projects (Contd..3), H1 2016 341
Myocardial Infarction - Dormant Projects (Contd..4), H1 2016 342
Myocardial Infarction - Dormant Projects (Contd..5), H1 2016 343
Myocardial Infarction - Dormant Projects (Contd..6), H1 2016 344
Myocardial Infarction - Dormant Projects (Contd..7), H1 2016 345
Myocardial Infarction - Dormant Projects (Contd..8), H1 2016 346
Myocardial Infarction - Discontinued Products, H1 2016 347